Chapter I. Pathogenesis
Rev Diabet Stud,
2012,
9(4):236-247 |
DOI 10.1900/RDS.2012.9.236 |
Metabolomics in the Studies of Islet Autoimmunity and Type 1 Diabetes
Matej Oresic
VTT Technical Research Centre of Finland, Tietotie 2, Espoo, FIN-02044 VTT, Finland
Manuscript submitted December 23, 2012; resubmitted January 21, 2013; accepted February 8, 2013.
Keywords: allostasis, autoimmunity, biomarker, lipid metabolism, lipidomics, metabolomics, systems biology
Abstract
The metabolome is sensitive to genetic and environmental factors contributing to complex diseases such as type 1 diabetes (T1D). Metabolomics is the study of biochemical and physiological processes involving metabolites. It is therefore one of the key platforms for the discovery and study of pathophysiological phenomena leading to T1D and the development of T1D-associated complications. Although the application of metabolomics in T1D research is still rare, metabolomic research has already advanced across the full spectrum, from disease progression to the development of diabetic complications. Metabolomic studies in T1D have contributed to an improved etiopathogenic understanding and demonstrated their potential in the clinic. For example, metabolomic data from recent T1D studies suggest that a specific metabolic profile, or metabotype, precedes islet autoimmunity and the development of overt T1D. These early metabolic changes are attributed to many biochemical pathways, thus suggesting a systemic change in metabolism which may be inborn. Based on this evidence, the role of the metabolome in the progression to T1D is therefore to facilitate specific biochemical processes associated with T1D, and to contribute to the development of a vulnerable state in which disease is more likely to be triggered. This may have important implications for the understanding of T1D pathophysiology and early disease detection and prevention.
Fulltext:
HTML
, PDF
(2.4 MB)
This article has been cited by other articles:
|
Metabolomics reveals new metabolic perturbations in children with type 1 diabetes
Galderisi A, Pirillo P, Moret V, Stocchero M, Gucciardi A, Perilongo G, Moretti C, Monciotti C, Giordano G, Baraldi E
Pediatr Diabetes 2017. In press
|
|
|
Tolerogenic Dendritic Cells from Poorly Compensated Type 1 Diabetes Patients Have Decreased Ability To Induce Stable Antigen-Specific T Cell Hyporesponsiveness and Generation of Suppressive Regulatory T Cells
Danova K, Grohova A, Strnadova P, Funda DP, Sumnik Z, Lebl J, Cinek O, Pruhova S, Kolouskova S, Obermannova B, Petruzelkova L, Sediva A, Fundova P, Buschard K, Spisek R, Palova-Jelinkova L
J Immunol 2017. 198(2):729-740
|
|
|
Mitochondrial aldehyde dehydrogenase 2 deficiency aggravates energy metabolism disturbance and diastolic dysfunction in diabetic mice
Wang C, Fan F, Cao Q, Shen C, Zhu H, Wang P, Zhao X, Sun X, Dong Z, Ma X, Liu X, Han S, Wu C, Zou Y, Hu K, Ge J, Sun A
J Mol Med (Berl) 2016. 94(11):1229-1240
|
|
|
Metabolomics applied to the pancreatic islet
Gooding JR, Jensen MV, Newgard CB
Arch Biochem Biophys 2016. 589:120-130
|
|
|
Modeling strategies to study metabolic pathways in progression to type 1 diabetes - Challenges and opportunities
Marinkovic T, Oresic M
Arch Biochem Biophys 2016. 589:131-137
|
|
|
Metabolomics in childhood diabetes
Frohnert BI, Rewers MJ
Pediatr Diabetes 2016. 17(1):3-14
|
|
|
Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association
Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, Greenbaum CJ, Herold KC, Krischer JP, Lernmark A, Ratner RE, Rewers MJ, Schatz DA, Skyler JS, Sosenko JM, Ziegler AG
Diabetes Care 2015. 38(10):1964-1974
|
|
|
Heterogeneity in diabetes-associated autoantibodies and susceptibility to Type 1 diabetes: lessons for disease prevention
Ilonen J, Knip M, Vaarala O
Exp Rev Endocrinol Metab 2015. 10(1):25-34
|
|
|
Systems biology strategies to study lipidomes in health and disease
Hyötyläinen T, Oresic M
Prog Lipid Res 2014. 55:43-60
|
|
|